- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Losartan linked to risk of hypotension and AKI among COVID-19 patients hospitalized for pneumonia: Study
A recent research by Karen Tran and colleagues suggested that angiotensin receptor blockers (ARBs) should not be added to the treatment of patients hospitalized for acute COVID-19. The findings of this study were published in the recent edition of Clinical Infectious Diseases journal.
COVID-19 resulted in several hospitalizations, ICU admissions and the requirement for life support. The randomized controlled studies used prophylactic anticoagulation, dexamethasone, immune regulators and Janus kinase inhibitors for patients admitted with acute COVID-19 which showed lower ventilation and death rates. This downregulates the angiotensin-converting enzyme 2 of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which may lead to an increase in angiotensin II. This study was set out to find if losartan is safe and reduces mortality in hospitalized COVID-19 patients when compared to standard treatment in patients hospitalized with acute COVID-19 infection.
Adults hospitalized with COVID-19 infections were included in this research. The patients with hypotension, hyperkalemia, acute renal damage and use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers during the previous seven days were excluded. The patients from 29 hospitals in France and Canada were randomized to receive standard care (control arm) or losartan 25–100 mg/day orally for the duration of the hospital stay or three months. The 28-day mortality rate was the primary measure. Hospital mortality, organ support, and serious adverse events (SAEs) were considered secondary outcomes.
There was a major safety risk with losartan that led to the early termination of the experiment. Compared to usual care groups, losartan had substantially higher rates of hypotension and any SAE in 341 patients in both intensive care and ward patients. Neither organ dysfunction nor secondary outcomes differed between losartan (6.5%) and usual care (5.9%) in terms of 28-day mortality.
The outcome of this research and the comprehensive literature point to significant safety concerns with the use of losartan and other ARBs in patients who are hospitalized for pneumonia. Overall, losartan did not change mortality or critical organ function when compared to conventional therapy in individuals hospitalized for acute COVID-19 without previous ARB exposure.
Source:
Tran, K. C., Asfar, P., Cheng, M., Demiselle, J., Singer, J., Lee, T., Sweet, D., Boyd, J., Walley, K., Haljan, G., Sharif, O., Geri, G., Auchabie, J., Quenot, J.-P., Lee, T. C., Tsang, J., Meziani, F., Lamontagne, F., … Dubee, V. (2024). Effects of Losartan on Patients Hospitalized for Acute Coronavirus Disease 2019: A Randomized Controlled Trial. In Clinical Infectious Diseases. Oxford University Press (OUP). https://doi.org/10.1093/cid/ciae306
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751